Postmenopausal hormone replacement therapy (HRT) may reduce progression of age-related maculopathy (ARM), according to the results of a cross-sectional study reported in the December issue of the American Journal of Ophthalmology.
‘Decisions regarding postmenopausal hormone therapies are becoming increasingly complex, and it is important to evaluate their effects, including testing their relationship to eye diseases of aging,’ lead author Johanna M. Seddon, MD, ScM, from the Massachusetts Eye and Ear Infirmary in Boston, Massachusetts, says in a news release.
Of 394 postmenopausal women aged 50 to 78 years with ARM, 193 had nonadvanced ARM and 201 had advanced ARM. Logistic regression analysis revealed that women with ARM who had used postmenopausal HRT in the past had half the risk of advanced ARM than did those who had never used HRT, after controlling for other known and potential risk factors (odds ratio [OR], 0.5; 95% confidence interval [CI], 0.30 – 0.98). Risk of advanced ARM was also higher in subjects with older age at menarche (OR, 1.16; 95% CI, 1.00 – 1.35).
לכתבה במדסקייפ
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!